InsidersTradesSigma
Track the Lexaria Bioscience Corp. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Health Care sector, Lexaria Bioscience Corp. has recorded 19 reports. Market capitalisation: €14.7m. The latest transaction was reported on 18 March 2026 (Don). Among the most active insiders: BUNKA CHRISTOPHER. Every trade is free.
19
Insider Decl.
n/a
Thresholds
€135,324
10 ops.
Buy Volume
€9,486
1 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,249 of 29,024 companies
25.0
score / 100
Value1
Quality49
FCF yld-120%
Earn yld-135%
EV/EBITDA·
ROE-163%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 March 2026
Declarations19 total
100,000 shares0common sharesSEC:0001103780-26-000001:0
15,600 shares@ US$0.921512.2% of flowcommon sharesSEC:0001348362-25-000016:0
Canonical exit: 27 Oct 2025 (T+90)
5,000 shares@ US$0.9063100.0% of flowcommon sharesSEC:0001348362-25-000015:0
Canonical exit: 27 Oct 2025 (T+90)
5,376 shares@ US$0.928100.0% of flowcommon sharesSEC:0001348362-25-000014:0
Canonical exit: 27 Oct 2025 (T+90)
750 shares@ US$0.914.6% of flowcommon sharesSEC:0001348362-25-000013:0
Canonical exit: 27 Oct 2025 (T+90)
15,000 shares@ US$0.909419.6% of flowcommon sharesSEC:0001348362-25-000012:0
Canonical exit: 27 Oct 2025 (T+90)
100,000 shares0Restricted Stock AwardSEC:0001348362-25-000001:0
22,828 shares@ US$2.2436100.0% of flowcommon sharesSEC:0001348362-24-000006:0
Canonical exit: 2 Mar 2025 (T+90)
1,600 shares@ US$3.1353.5% of flowcommon sharesSEC:0001855763-24-000013:0
Canonical exit: 10 Nov 2024 (T+90)
2,567 shares@ US$4.0078.1% of flowcommon sharesSEC:0001855763-24-000012:0
2,500 shares@ US$1.1521.9% of flowcommon sharesSEC:0001855763-24-000011:0
1,500 shares@ US$2.844646.5% of flowCommon SharesSEC:0001855763-23-000001:0
Canonical exit: 10 May 2023 (T+90)
21,900 shares@ US$1.98850.0% of flowcommon sharesSEC:0001855763-22-000019:0
Canonical exit: 10 Jan 2023 (T+90)
121 shares@ US$2.0950.0% of flowcommon sharesSEC:0001855763-22-000020:0
Canonical exit: 12 Jan 2023 (T+90)
121 shares@ US$2.0950.0% of flowcommon sharesSEC:0001855763-22-000018:0
21,900 shares@ US$1.98850.0% of flowcommon sharesSEC:0001855763-22-000014:0
5,000 shares@ US$1.9580.063% mcap57.7% of flowcommon sharesSEC:0001855763-22-000006:0
1,799 shares@ US$2.0070.024% mcap21.6% of flowcommon sharesSEC:0001855763-22-000005:0
1,700 shares@ US$2.0080.023% mcap20.6% of flowcommon sharesSEC:0001855763-22-000004:0
19 of 19 declarations
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a company focused on developing delivery technologies for cannabinoids and other bioactive molecules. It aims to enhance the absorption and efficacy of cannabinoid-based products.